Ceftriaxone Resistance in S. pneumoniae Infections

Interpretation of Surveillance Data

When resistance is "lower for invasive infections," this typically means that invasive isolates show better susceptibility profiles than non-invasive respiratory isolates, as reported by the Infectious Diseases Society of America 1, 2, 3
The "except for ceftriaxone" clause indicates that ceftriaxone did not follow this pattern—meaning resistance rates were similar between invasive and non-invasive infections, according to the Clinical Microbiology and Infection guidelines 1, 2

Among parenteral cephalosporins, cefotaxime and ceftriaxone demonstrate good activity against penicillin-resistant S. pneumoniae, unlike other third-generation agents such as ceftazidime, as stated by the American Academy of Microbiology 1, 2, 3, 4
Ceftriaxone MICs are typically 2-4 times lower than penicillin MICs against the same organism, providing a therapeutic advantage, according to the European Society of Clinical Microbiology and Infectious Diseases 1, 2, 3

The American Academy of Otolaryngology-Head and Neck Surgery recommends ceftriaxone or cefotaxime as preferred parenteral agents for severe pneumococcal infections, due to their high coverage rates 5
Parenteral ceftriaxone maintains >99% coverage even against intermediately resistant strains in hospitalized or severe infections, as reported by the Infectious Diseases Society of America 5
Ceftriaxone demonstrates bactericidal activity against 92.9% of pneumococcal strains, including penicillin-resistant isolates, according to the Clinical Microbiology and Infection guidelines 1, 2, 3

Do not confuse "penicillin resistance" with "ceftriaxone resistance"—these are distinct resistance patterns, and penicillin-resistant strains often remain ceftriaxone-susceptible, as stated by the American Academy of Microbiology 1, 2, 3, 5
Do not assume all third-generation cephalosporins are equivalent—ceftazidime is 8-16-fold less active than ceftriaxone against S. pneumoniae, according to the European Society of Clinical Microbiology and Infectious Diseases 1, 2, 3